XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 29, 2024
Dec. 29, 2023
Current assets:    
Cash and cash equivalents $ 259,561 $ 262,994
Short-term investments 703,695 732,308
Trade receivables, net 240,577 237,407
Inventory 21,106 17,323
Prepaid expenses and other current assets 67,490 67,926
Total current assets 1,292,429 1,317,958
Long-term investments 629,561 728,717
Property and equipment, net 127,222 128,731
Deferred tax assets, net 361,578 361,145
Goodwill 63,684 63,684
Right-of-use assets and other 329,278 342,122
Total assets 2,803,752 2,942,357
Current liabilities:    
Accounts payable 26,069 33,768
Accrued compensation and benefits 72,958 93,325
Accrued clinical trial liabilities 59,337 71,615
Rebates and fees due to customers 75,651 59,619
Accrued collaboration liabilities 34,704 27,533
Other current liabilities 104,291 108,417
Total current liabilities 373,010 394,277
Long-term portion of operating lease liabilities 201,466 189,944
Other long-term liabilities 101,268 94,224
Total liabilities 675,744 678,445
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 295,032 and 302,793 at March 31, 2024, and December 31, 2023, respectively 295 303
Additional paid-in capital 2,391,865 2,440,710
Accumulated other comprehensive loss (5,204) (3,750)
Accumulated deficit (258,948) (173,351)
Total stockholders’ equity 2,128,008 2,263,912
Total liabilities and stockholders' equity $ 2,803,752 $ 2,942,357